Reviewed by the Help Dementia Editorial Team — our editors review every article for accuracy against guidance from the National Institute on Aging, the Alzheimer’s Association, and peer-reviewed sources.
Medication side sits at the center of this dementia and brain health question.
Yes, medication side effects can meaningfully change MMSE scores, and these changes matter in clinical practice. When patients take certain medications—particularly anticholinergic drugs, sedatives, and some antidepressants—their Mini-Mental State Examination scores can decline faster than they would without medication exposure. A 2024 study demonstrated this concretely: patients with moderate cumulative exposure to anticholinergic and sedative medications experienced cognitive decline at a rate of 1.74 points per year on the MMSE, compared to 1.26 points per year for patients with no exposure.
That 0.48 point-per-year acceleration reflects real changes in cognition that show up on standardized tests. For someone undergoing dementia evaluation, this distinction is clinically critical. An MMSE decline might reflect medication effects rather than underlying neurodegeneration, which means the problem could be reversed or slowed by adjusting prescriptions. This is why clinicians routinely investigate medication side effects when MMSE scores are abnormal—it’s one of the few potentially reversible causes that can be identified and addressed.
Table of Contents
- What Does the MMSE Measure and How Do Medications Interfere?
- Anticholinergic and Sedative Medications—The Biggest Culprits
- Antidepressants and the Acute Cognitive Response
- How Diabetes Medications Show Divergent Cognitive Effects
- Why Medication Side Effects Can Be Mistaken for Dementia
- Multiple Medications and Cumulative Effects
- Moving Forward in Dementia Care and Medication Management
- Conclusion
What Does the MMSE Measure and How Do Medications Interfere?
The Mini-Mental State Examination tests orientation, memory, attention, language, and visual-spatial skills, with a maximum score of 30 points. Scores between 27 and 30 are considered normal cognitive function, while 21 to 26 suggest mild cognitive impairment. Below 24 is commonly flagged as indicating cognitive impairment, though the threshold varies depending on a person’s education level and age. The test itself takes about 10 minutes and has been in clinical use for decades.
Medications interfere with mmse performance by affecting the exact domains the test measures. Anticholinergic drugs—which block a neurotransmitter called acetylcholine—impair attention and memory formation directly. Sedative medications slow processing speed and cloud consciousness, making it harder to focus during testing. Some antidepressants cause a type of acute cognitive fog early in treatment. None of these effects necessarily mean permanent brain damage, but they do produce measurable changes in test scores that can be mistaken for dementia progression if the medications aren’t considered.
Anticholinergic and Sedative Medications—The Biggest Culprits
Anticholinergic and sedative drugs stand out as the strongest medication disruptors of MMSE scores. Common examples include certain antihistamines (like diphenhydramine), some antidepressants (like tricyclic antidepressants), anticholinergic medications for bladder or gastrointestinal issues, and benzodiazepines used for anxiety or sleep. The 2024 research found that even moderate cumulative exposure to these drug classes accelerated cognitive decline by about one-third compared to no exposure—that’s the difference between losing 1.26 points and 1.74 points each year on the MMSE.
The limitation here is that older adults often need these medications for legitimate medical reasons. Someone with overactive bladder, for instance, might benefit significantly from an anticholinergic medication despite the cognitive trade-off. This creates a real clinical dilemma: the benefit of treating one condition has to be weighed against the risk of accelerated cognitive decline. It’s not always possible to simply stop the medication, so patients and doctors sometimes have to accept a trade-off or look for alternative medications in the same class that have lower anticholinergic activity.
Antidepressants and the Acute Cognitive Response
SSRIs (selective serotonin reuptake inhibitors) deserve special attention because they’re prescribed to a large fraction of older adults, often specifically for depression alongside dementia. Clinical research shows that MMSE scores can show gradual decline during the acute phase of SSRI treatment—meaning the first few weeks or months. This isn’t because SSRIs permanently damage cognition, but because the brain is adjusting to changes in serotonin levels, which affects attention and processing speed during that adaptation period.
In practice, this means an MMSE test given soon after starting an SSRI might show a temporary dip, even though the patient may stabilize cognitively once the medication reaches steady state, or even improve as depression lifts. This underscores why timing matters: an MMSE score has to be interpreted in context of when medications were started, changed, or stopped. A single low score without that context can lead to an unnecessary dementia diagnosis.
How Diabetes Medications Show Divergent Cognitive Effects
One of the more surprising findings from recent research is that not all medications in the same disease category affect cognition the same way. Among diabetes medications specifically, metformin and DPP-4 inhibitors were associated with slower cognitive decline over time, while insulin and sulfonylureas showed larger point-wise decreases in MMSE scores compared to DPP-4 users.
This matters because it suggests that if someone with both diabetes and early cognitive decline is struggling, their cognitive issues might partly be driven by their diabetes medication choice rather than their diabetes itself. The practical trade-off is that metformin and DPP-4 inhibitors may need to be prioritized for diabetic patients at risk of cognitive impairment, even if other diabetes medications work slightly better for blood sugar control. This is one example of how personalized medicine thinking has to enter these decisions—the “best” medication for one condition might not be best when another condition is also present.
Why Medication Side Effects Can Be Mistaken for Dementia
One of the biggest clinical warnings is that medication-induced cognitive decline can look identical to dementia progression on an MMSE test. Both show as declining scores over time, both can present with memory loss or attention problems, and both require a clinical visit to evaluate. The danger is that if a doctor doesn’t systematically review medications, they might diagnose dementia and start the patient on dementia medications (like cholinesterase inhibitors) when the real problem is a reversible drug effect.
This is why standard clinical practice includes investigating medication side effects as a reversible cause whenever MMSE scores are abnormal. Vitamin B12 deficiency, thyroid dysfunction, and depression are also routinely checked because they can mimic dementia but are treatable. The limitation of the MMSE itself is that it can’t distinguish between these causes—it just measures the result. The test is useful for detecting cognitive impairment, but diagnosis requires the full clinical picture.
Multiple Medications and Cumulative Effects
Most older adults taking medications that affect cognition aren’t taking just one—they’re often on several. An 80-year-old with arthritis, anxiety, sleep problems, and overactive bladder might be on an NSAID, a benzodiazepine, a sleep aid, and an anticholinergic all at the same time. The cognitive effects can be cumulative and unpredictable: the combination might be far worse than any single medication alone.
This cumulative exposure is what the 2024 study measured—not just whether someone took anticholinergic medications, but how much total exposure they accumulated. For example, someone taking a low-dose anticholinergic medication consistently for a year, plus occasional benzodiazepines for anxiety, might show noticeably greater MMSE decline than someone taking neither. Recognizing this cumulative effect is important because it points to a potential solution: sometimes reducing the total medication burden, even if no single medication is “bad,” can stabilize or improve cognition.
Moving Forward in Dementia Care and Medication Management
As the population ages and polypharmacy (taking multiple medications) becomes more common, the question of medication effects on cognition will only grow more important. Current clinical practice is to screen for medication contributions to cognitive decline, but this screening sometimes happens too late—after a questionable dementia diagnosis has already been made. Future approaches may include more systematic medication reviews at the first sign of cognitive change, with formal tools to quantify anticholinergic burden and sedative exposure before cognitive testing.
The takeaway is that an MMSE score should never be interpreted in isolation from medication history. If someone’s score has declined, that change might be signaling dementia, but it might also be signaling that a medication adjustment is needed. The good news is that unlike true neurodegenerative dementia, medication-driven cognitive decline is often reversible.
Conclusion
Medication side effects are a real and documented cause of MMSE score changes, with anticholinergic drugs, sedatives, and certain antidepressants showing the strongest effects. The 2024 research showing that these medications accelerate cognitive decline by nearly 40% compared to no exposure gives concrete numbers to what clinicians have long suspected. Because these effects are potentially reversible, they’re worth investigating systematically whenever MMSE scores are abnormal.
If you or a family member are facing questions about changing MMSE scores during dementia evaluation, medication history should be part of the conversation with your doctor. A comprehensive medication review, possibly with a pharmacist, can identify which drugs might be contributing to cognitive changes and whether alternatives exist. Cognition is too important to attribute to dementia without first ruling out reversible causes.
You Might Also Like
- Can Delirium Cause a Low MMSE Score?
- MoCA Scores After Surgery: Why Cognition Can Change
- Can an MMSE Score Improve After Treatment?
For more, see Alzheimer’s Association — caregiving.
